Deutsche Bank launched formal coverage on several equities it believes present investment opportunities tied to diabetes management and to companies with business models adjacent to healthcare. Analysts at the bank signaled greater confidence in the markets for continuous glucose monitoring (CGM) and insulin pumps, noting that recent share-price weakness has created more attractive valuations. Their notes also extend beyond pure medical-device specialists to include firms in packaging and data-center infrastructure that touch healthcare supply chains.
DexCom (NASDAQ:DXCM) was initiated with a Buy rating and an $86 price objective, which the bank says implies roughly 25% potential upside. Deutsche Bank’s analysts indicated that fears about CGM market growth have eased following the company’s recent investor day. They cited expanding insurance coverage for type-2 diabetes patients who do not use insulin, the commercial rollout of a 15-day sensor, and margin improvement as drivers that should support stronger earnings and valuation. The research note also expressed an expectation that management will revert to a more consistent beat-and-raise cadence.
Separately, DexCom announced it obtained FDA clearance to use its Stelo Glucose Biosensor in pediatric patients ages 2 and older. The company has also drawn an analyst-side upgrade: TD Cowen raised its price target on DexCom shares to $95. Market price movements reflected some investor interest in the name, with a portion of trading registering a positive intraday change.
Insulet (NASDAQ:PODD) received a Buy initiation with a $190 price target from Deutsche Bank, representing an implied upside near 37%. Bank analysts argued that recent weakness in Insulet’s share price has created what they view as an appealing entry point, with competitive concerns and the potential effects of GLP-1 drugs already reflected in the current valuation. They pointed to Insulet’s leadership position in tubeless insulin pumps and a durable growth profile, saying further gains are plausible if execution remains strong.
Credit-rating news has introduced some caution around Insulet: Moody’s revised the company outlook to negative from stable, citing concerns related to product recalls. In governance changes reported by the company, Insulet appointed Jonathan Mazelsky as an independent director to its board.
Tandem Diabetes Care (NASDAQ:TNDM) was initiated at Hold with a $15.50 price target, which Deutsche Bank estimates implies about 8% upside. The analysts acknowledged Tandem’s progress in improving margins and its strategic move toward pharmacy-based reimbursement, but they flagged remaining execution risks in the transition away from traditional durable medical equipment reimbursement. Those execution uncertainties are why the bank restrained its near-term rating despite positive operational signs.
Tandem has secured regulatory momentum abroad, receiving a CE mark in Europe for expanded indications of its insulin delivery systems. In addition, Wells Fargo recently upgraded the company’s rating to Overweight from Equal Weight.
Smurfit Westrock (NYSE:SW) was introduced with a Buy rating and a $57 price target, implying roughly 26% upside according to Deutsche Bank. The analysts argued the market is underestimating the potential to lift profitability by applying Smurfit Kappa’s operating model across WestRock’s North American assets. They emphasized disciplined capital allocation, a progressive dividend stance, and management’s long-range target of reaching about $7 billion in adjusted EBITDA by 2030.
For the first quarter of 2026, Smurfit Westrock reported earnings per share of $0.33, which missed analysts’ forecasts, while revenue came in at $7.71 billion, beating expectations. The company also completed the delisting of its shares from the London Stock Exchange.
Market context and breadth of coverage
Deutsche Bank’s coverage underscores a focus on the diabetes device market where CGMs and insulin pumps are central themes. The research team framed several ideas as either direct healthcare plays or healthcare-adjacent opportunities - the latter category including packaging and data-center infrastructure assets that support distribution, logistics and digital health platforms.
Observed intraday price moves for the names discussed included modest gains for DXCM, PODD, TNDM and SW during reported sessions.
Analytical takeaway
Deutsche Bank’s initiation notes emphasize valuation opportunity after recent share weakness, product and reimbursement developments that could expand addressable markets, and company-specific operational levers such as margin improvement and capital allocation. At the same time, the bank flagged areas of uncertainty - notably execution risk for companies undergoing reimbursement transitions and credit/outlook pressures tied to product issues.